Company News

In the intricate design of therapeutic oligonucleotides, the orientation of the sugar-phosphate backbone can profoundly influence biological activity. Cosperpharma is proud to introduce our specialized line of 2'-OMe-Reverse Phosphoramidites. These unique monomers feature a 3'-DMT protection strategy, enabling the synthesis of oligonucleotides with reversed internucleotide linkages. This capability is essential for creating nuclease-resistant 3'-3' or 5'-5' capped structures, which are critical for extending the half-life and enhancing the potency of antisense and siRNA therapeutics.

In the development of therapeutic oligonucleotides, the phosphorothioate (PS) backbone modification is one of the most widely employed strategies for improving pharmacokinetic properties. Cosperpharma is pleased to introduce our high-purity DNA-Thiophosphoramidites. By substituting a sulfur atom for one of the non-bridging oxygen atoms in the phosphate backbone, these specialized monomers confer enhanced nuclease resistance and improved protein binding. Our comprehensive portfolio includes all four standard DNA bases, providing researchers with the essential building blocks for developing robust antisense therapeutics and diagnostic tools.

As RNA therapeutics continue to advance, the demand for diverse and highly specific modified nucleosides has never been greater. Cosperpharma is proud to announce our expanded portfolio of Pseudouridine Phosphoramidites, offering researchers a versatile toolkit to optimize their mRNA and oligonucleotide designs. Whether you require 2'-OMe, 2'-deoxy, or 2'-O-TBDMS variants, our comprehensive range provides the flexibility needed to fine-tune stability, translational efficiency, and immune response for your specific application.

The success of mRNA-based vaccines and therapeutics has fundamentally changed the landscape of medicine, and at the heart of this revolution lies the strategic use of modified nucleosides. Cosperpharma is proud to introduce our high-purity DMT-2'-OMe-N1-methyl-Pseudouridine-CE-Phosphoramidite. As a critical building block for next-generation mRNA therapeutics, this specialized monomer enables researchers to incorporate N1-methyl-pseudouridine (m1Ψ) into synthetic RNA, significantly enhancing translational efficiency and dampening innate immune responses.

In the pursuit of highly specific and stable oligonucleotide therapeutics, the 2'-O-4'-C-Locked modification stands as a pinnacle of nucleic acid chemistry. Cosperpharma is proud to introduce our premium line of 2'-O-4'-C-Locked Phosphoramidites (commonly known as LNA). By bridging the 2' and 4' positions of the ribose ring, these monomers "lock" the sugar into a rigid C3'-endo conformation. This unique structure delivers unparalleled thermal stability and mismatch discrimination, making them indispensable for designing advanced diagnostics, antisense oligonucleotides, and CRISPR guide RNAs.

As the field of nucleic acid therapeutics rapidly evolves, researchers require specialized building blocks to overcome biological barriers. Cosperpharma is proud to offer a premium selection of 2'-O-Methoxyethyl (MOE) Phosphoramidites. Renowned for their ability to significantly enhance nuclease resistance and binding affinity, MOE modifications are a cornerstone of successful antisense oligonucleotide (ASO) and siRNA development. Our high-purity monomers, including both standard and 5-Methyl variants, are designed to meet the rigorous demands of modern drug discovery and development.